GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus, an insulin glargine injection and Sanofi's most widely ...

28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly (LLY). Launched in 2022, the collaboration aims to deliver a ...

engaged with the local regulatory authorities to obtain approval of the insulin glargine injection, and released the first batch of the locally manufactured insulin drug product. Additionally ...

The official spokesperson for the Ministry of Health and Population Hossam Abdel-Ghaffar announced details on the extended-release for the first locally produced batch of insulin “Glargine”, in ...

Insulin glargine works gradually over approximately 24 hours and, like other types of insulin, helps maintain near-normal blood sugar levels in people with diabetes. Minister Abdel-Ghaffar noted ...